An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease
2020 ◽
Vol 79
(Suppl 1)
◽
pp. 66.2-66
2018 ◽
Vol 141
(2)
◽
pp. AB26
2004 ◽
Vol 128
(1)
◽
pp. 23-31
2010 ◽
Vol 161
(3)
◽
pp. 518-526
◽
2012 ◽
Vol 129
(2)
◽
pp. AB15
◽
2017 ◽
Vol 139
(2)
◽
pp. AB217